<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20241116231315
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20241116231315" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sun, 17 Nov 2024 04:13:15 +0000</lastbuilddate>
<pubDate>Sat, 16 Nov 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Heart Failure in Zero Gravity-External Constraint and Cardiac Hemodynamics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39549275/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116231315&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 16. doi: 10.1001/jamacardio.2024.4596. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39549275/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116231315&v=2.18.0.post9+e462414">39549275</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4596>10.1001/jamacardio.2024.4596</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39549275</guid>
<pubDate>Sat, 16 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>James P MacNamara</dc:creator>
<dc:creator>Christopher M Hearon</dc:creator>
<dc:creator>Giorgio Manferdelli</dc:creator>
<dc:creator>Aman M Shah</dc:creator>
<dc:creator>Kevin G Tayon</dc:creator>
<dc:creator>Ambarish Pandey</dc:creator>
<dc:creator>Satyam Sarma</dc:creator>
<dc:creator>Benjamin D Levine</dc:creator>
<dc:date>2024-11-16</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Heart Failure in Zero Gravity-External Constraint and Cardiac Hemodynamics</dc:title>
<dc:identifier>pmid:39549275</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4596</dc:identifier>
</item>
<item>
<title>Temporal Effects of Plozasiran on Lipids and Lipoproteins in Persistent Chylomicronemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39549263/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116231315&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 16. doi: 10.1161/CIRCULATIONAHA.124.072860. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39549263/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116231315&v=2.18.0.post9+e462414">39549263</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072860>10.1161/CIRCULATIONAHA.124.072860</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39549263</guid>
<pubDate>Sat, 16 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Gerald F Watts</dc:creator>
<dc:creator>Robert A Hegele</dc:creator>
<dc:creator>Robert S Rosenson</dc:creator>
<dc:creator>Ira J Goldberg</dc:creator>
<dc:creator>Antonio Gallo</dc:creator>
<dc:creator>Ann Mertens</dc:creator>
<dc:creator>Alexis Baass</dc:creator>
<dc:creator>Rong Zhou</dc:creator>
<dc:creator>Ma'an Muhsin</dc:creator>
<dc:creator>Jennifer Hellawell</dc:creator>
<dc:creator>Daniel Gaudet</dc:creator>
<dc:creator>Nicholas J Leeper</dc:creator>
<dc:creator>PALISADE Study Group</dc:creator>
<dc:date>2024-11-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Temporal Effects of Plozasiran on Lipids and Lipoproteins in Persistent Chylomicronemia</dc:title>
<dc:identifier>pmid:39549263</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072860</dc:identifier>
</item>
<item>
<title>Family matters: health policies to tackle cardiomyopathies across Europe</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39548843/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116231315&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 16:ehae419. doi: 10.1093/eurheartj/ehae419. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39548843/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116231315&v=2.18.0.post9+e462414">39548843</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae419>10.1093/eurheartj/ehae419</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39548843</guid>
<pubDate>Sat, 16 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:creator>Cardiomyopathies Matter Initiative</dc:creator>
<dc:date>2024-11-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Family matters: health policies to tackle cardiomyopathies across Europe</dc:title>
<dc:identifier>pmid:39548843</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae419</dc:identifier>
</item>
<item>
<title>Revascularization in frail patients with acute coronary syndromes: a retrospective longitudinal study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39548842/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116231315&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Frailty is common in people presenting with ACS, where cardiovascular causes are the principal mode of death. Revascularization is associated with short- and long-term survival benefits in people at intermediate and high risk of frailty after adjustment for measured and unmeasured confounders.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 16:ehae755. doi: 10.1093/eurheartj/ehae755. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Frailty is increasingly prevalent in people presenting with acute coronary syndrome (ACS). This high-risk group is typically excluded from trials of interventions in ACS, and there is uncertainty about the risks and benefits of invasive management.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with an ACS diagnosis between 2010 and 2015 in England were identified from Hospital Episode Statistics, with linked Office for National Statistics mortality data. Frailty was defined by the Hospital Frailty Risk Score. Causal inference analysis used regional variation in revascularization as an instrumental variable to estimate average treatment effects of revascularization on cardiovascular mortality up to 5 years in people presenting with ACS and low-, intermediate-, or high-risk frailty.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The analysis included 565 378 ACS patients, of whom 11.6% (n = 65 522) were at intermediate risk and 4.7% (n = 26 504) were at high risk of frailty. Intermediate and high frailty risks were associated with reduced likelihood of echocardiography, invasive angiography, or revascularization and increased likelihood of mortality and major adverse cardiovascular events compared with low frailty risk. Cardiovascular death at 5 years was 78.6%, 77.3%, and 75.7% in people at low, intermediate, and high frailty risk, respectively. Instrumental variable analysis suggested that revascularization resulted in a higher absolute reduction in cardiovascular mortality in high and intermediate frail risk patients compared with low risk at 1-year post-ACS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Frailty is common in people presenting with ACS, where cardiovascular causes are the principal mode of death. Revascularization is associated with short- and long-term survival benefits in people at intermediate and high risk of frailty after adjustment for measured and unmeasured confounders.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39548842/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116231315&v=2.18.0.post9+e462414">39548842</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae755>10.1093/eurheartj/ehae755</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39548842</guid>
<pubDate>Sat, 16 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Marius Roman</dc:creator>
<dc:creator>Joanne Miksza</dc:creator>
<dc:creator>Florence Yuk-Lin Lai</dc:creator>
<dc:creator>Shirley Sze</dc:creator>
<dc:creator>Katrina Poppe</dc:creator>
<dc:creator>Rob Doughty</dc:creator>
<dc:creator>Iain Squire</dc:creator>
<dc:creator>Gavin James Murphy</dc:creator>
<dc:date>2024-11-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Revascularization in frail patients with acute coronary syndromes: a retrospective longitudinal study</dc:title>
<dc:identifier>pmid:39548842</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae755</dc:identifier>
</item>
<item>
<title>Trials and tribulations of cell therapy for heart failure: an update on ongoing trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39548233/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116231315&amp;v=2.18.0.post9+e462414
      <description>Heart failure (HF) remains a leading cause of mortality, responsible for 13% of all deaths worldwide. The prognosis for patients with HF is poor, with only a 50% survival rate within 5 years. A major challenge of ischaemia-driven HF is the loss of cardiomyocytes, compounded by the minimal regenerative capacity of the adult heart. To date, replacement of irreversibly damaged heart muscle can only be achieved by complete heart transplantation. In the past 20 years, cell therapy has emerged and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Nov 15. doi: 10.1038/s41569-024-01098-8. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Heart failure (HF) remains a leading cause of mortality, responsible for 13% of all deaths worldwide. The prognosis for patients with HF is poor, with only a 50% survival rate within 5 years. A major challenge of ischaemia-driven HF is the loss of cardiomyocytes, compounded by the minimal regenerative capacity of the adult heart. To date, replacement of irreversibly damaged heart muscle can only be achieved by complete heart transplantation. In the past 20 years, cell therapy has emerged and evolved as a promising avenue for cardiac repair and regeneration. During this time, cell therapy for HF has encountered substantial barriers in both preclinical studies and clinical trials but the field continues to progress and evolve from lessons learned from such research. In this Review, we provide an overview of ongoing trials of cell-based and cell product-based therapies for the treatment of HF. Findings from these trials will facilitate the clinical translation of cardiac regenerative and reparative therapies not only by evaluating the safety and efficacy of specific cell-based therapeutics but also by establishing the feasibility of novel or underexplored treatment protocols such as repeated intravenous dosing, personalized patient selection based on pharmacogenomics, systemic versus intramural cell delivery, and epicardial engraftment of engineered tissue products.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39548233/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116231315&v=2.18.0.post9+e462414">39548233</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01098-8>10.1038/s41569-024-01098-8</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39548233</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jianyi Jay Zhang</dc:creator>
<dc:creator>Steven M Pogwizd</dc:creator>
<dc:creator>Keiichi Fukuda</dc:creator>
<dc:creator>Wolfram-Hubertus Zimmermann</dc:creator>
<dc:creator>Chengming Fan</dc:creator>
<dc:creator>Joshua M Hare</dc:creator>
<dc:creator>Roberto Bolli</dc:creator>
<dc:creator>Philippe Menasché</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Trials and tribulations of cell therapy for heart failure: an update on ongoing trials</dc:title>
<dc:identifier>pmid:39548233</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01098-8</dc:identifier>
</item>
<item>
<title>STK19 facilitates the clearance of lesion-stalled RNAPII during transcription-coupled DNA repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39547229/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116231315&amp;v=2.18.0.post9+e462414
      <description>Transcription-coupled DNA repair (TCR) removes bulky DNA lesions impeding RNA polymerase II (RNAPII) transcription. Recent studies have outlined the stepwise assembly of TCR factors CSB, CSA, UVSSA, and transcription factor IIH (TFIIH) around lesion-stalled RNAPII. However, the mechanism and factors required for the transition to downstream repair steps, including RNAPII removal to provide repair proteins access to the DNA lesion, remain unclear. Here, we identify STK19 as a TCR factor...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 11:S0092-8674(24)01200-5. doi: 10.1016/j.cell.2024.10.018. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Transcription-coupled DNA repair (TCR) removes bulky DNA lesions impeding RNA polymerase II (RNAPII) transcription. Recent studies have outlined the stepwise assembly of TCR factors CSB, CSA, UVSSA, and transcription factor IIH (TFIIH) around lesion-stalled RNAPII. However, the mechanism and factors required for the transition to downstream repair steps, including RNAPII removal to provide repair proteins access to the DNA lesion, remain unclear. Here, we identify STK19 as a TCR factor facilitating this transition. Loss of STK19 does not impact initial TCR complex assembly or RNAPII ubiquitylation but delays lesion-stalled RNAPII clearance, thereby interfering with the downstream repair reaction. Cryoelectron microscopy (cryo-EM) and mutational analysis reveal that STK19 associates with the TCR complex, positioning itself between RNAPII, UVSSA, and CSA. The structural insights and molecular modeling suggest that STK19 positions the ATPase subunits of TFIIH onto DNA in front of RNAPII. Together, these findings provide new insights into the factors and mechanisms required for TCR.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39547229/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116231315&v=2.18.0.post9+e462414">39547229</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.018>10.1016/j.cell.2024.10.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39547229</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Diana van den Heuvel</dc:creator>
<dc:creator>Marta Rodríguez-Martínez</dc:creator>
<dc:creator>Paula J van der Meer</dc:creator>
<dc:creator>Nicolas Nieto Moreno</dc:creator>
<dc:creator>Jiyoung Park</dc:creator>
<dc:creator>Hyun-Suk Kim</dc:creator>
<dc:creator>Janne J M van Schie</dc:creator>
<dc:creator>Annelotte P Wondergem</dc:creator>
<dc:creator>Areetha D'Souza</dc:creator>
<dc:creator>George Yakoub</dc:creator>
<dc:creator>Anna E Herlihy</dc:creator>
<dc:creator>Krushanka Kashyap</dc:creator>
<dc:creator>Thierry Boissière</dc:creator>
<dc:creator>Jane Walker</dc:creator>
<dc:creator>Richard Mitter</dc:creator>
<dc:creator>Katja Apelt</dc:creator>
<dc:creator>Klaas de Lint</dc:creator>
<dc:creator>Idil Kirdök</dc:creator>
<dc:creator>Mats Ljungman</dc:creator>
<dc:creator>Rob M F Wolthuis</dc:creator>
<dc:creator>Patrick Cramer</dc:creator>
<dc:creator>Orlando D Schärer</dc:creator>
<dc:creator>Goran Kokic</dc:creator>
<dc:creator>Jesper Q Svejstrup</dc:creator>
<dc:creator>Martijn S Luijsterburg</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>STK19 facilitates the clearance of lesion-stalled RNAPII during transcription-coupled DNA repair</dc:title>
<dc:identifier>pmid:39547229</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.018</dc:identifier>
</item>
<item>
<title>STK19 positions TFIIH for cell-free transcription-coupled DNA repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39547228/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116231315&amp;v=2.18.0.post9+e462414
      <description>In transcription-coupled nucleotide excision repair (TC-NER), stalled RNA polymerase II (RNA Pol II) binds CSB and CRL4^(CSA), which cooperate with UVSSA and ELOF1 to recruit TFIIH. To explore the mechanism of TC-NER, we recapitulated this reaction in vitro. When a plasmid containing a site-specific lesion is transcribed in frog egg extract, error-free repair is observed that depends on CSB, CRL4^(CSA), UVSSA, and ELOF1. Repair also requires STK19, a factor previously implicated in transcription...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 12:S0092-8674(24)01202-9. doi: 10.1016/j.cell.2024.10.020. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In transcription-coupled nucleotide excision repair (TC-NER), stalled RNA polymerase II (RNA Pol II) binds CSB and CRL4<sup>CSA</sup>, which cooperate with UVSSA and ELOF1 to recruit TFIIH. To explore the mechanism of TC-NER, we recapitulated this reaction in vitro. When a plasmid containing a site-specific lesion is transcribed in frog egg extract, error-free repair is observed that depends on CSB, CRL4<sup>CSA</sup>, UVSSA, and ELOF1. Repair also requires STK19, a factor previously implicated in transcription recovery after UV exposure. A 1.9-Å cryo-electron microscopy structure shows that STK19 binds the TC-NER complex through CSA and the RPB1 subunit of RNA Pol II. Furthermore, AlphaFold predicts that STK19 interacts with the XPD subunit of TFIIH, and disrupting this interface impairs cell-free repair. Molecular modeling suggests that STK19 positions TFIIH ahead of RNA Pol II for lesion verification. Our analysis of cell-free TC-NER suggests that STK19 couples RNA Pol II stalling to downstream repair events.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39547228/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116231315&v=2.18.0.post9+e462414">39547228</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.020>10.1016/j.cell.2024.10.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39547228</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Tycho E T Mevissen</dc:creator>
<dc:creator>Maximilian Kümmecke</dc:creator>
<dc:creator>Ernst W Schmid</dc:creator>
<dc:creator>Lucas Farnung</dc:creator>
<dc:creator>Johannes C Walter</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>STK19 positions TFIIH for cell-free transcription-coupled DNA repair</dc:title>
<dc:identifier>pmid:39547228</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.020</dc:identifier>
</item>
<item>
<title>SnapShot: Targeted protein degradation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39547212/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116231315&amp;v=2.18.0.post9+e462414
      <description>Targeted protein degradation strategies leverage endogenous cellular degradation machinery to selectively eliminate a protein of interest. Emerging technologies are opening avenues in drug discovery and functional characterization of intracellular, membrane, and extracellular proteins. To view this SnapShot, open or download the PDF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 14;187(23):6784-6784.e1. doi: 10.1016/j.cell.2024.10.025.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Targeted protein degradation strategies leverage endogenous cellular degradation machinery to selectively eliminate a protein of interest. Emerging technologies are opening avenues in drug discovery and functional characterization of intracellular, membrane, and extracellular proteins. To view this SnapShot, open or download the PDF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39547212/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116231315&v=2.18.0.post9+e462414">39547212</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.025>10.1016/j.cell.2024.10.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39547212</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Yu Ding</dc:creator>
<dc:creator>Boxun Lu</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>SnapShot: Targeted protein degradation</dc:title>
<dc:identifier>pmid:39547212</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.025</dc:identifier>
</item>
<item>
<title>Bound by the love for cholesterol: A transporter meets a GPCR</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39547211/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116231315&amp;v=2.18.0.post9+e462414
      <description>In a recently published article in Nature, Bayly-Jones et al. report the cryo-EM structures of a lysosomal cholesterol sensor, LYCHOS, also known as GPR155, which reveals a unique fusion of a plant auxin-transporter-like domain with a seven-transmembrane GPCR-like domain and elucidates mechanistic insights into cellular regulation of mTORC1 activity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 14;187(23):6518-6520. doi: 10.1016/j.cell.2024.10.033.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In a recently published article in Nature, Bayly-Jones et al. report the cryo-EM structures of a lysosomal cholesterol sensor, LYCHOS, also known as GPR155, which reveals a unique fusion of a plant auxin-transporter-like domain with a seven-transmembrane GPCR-like domain and elucidates mechanistic insights into cellular regulation of mTORC1 activity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39547211/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116231315&v=2.18.0.post9+e462414">39547211</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.033>10.1016/j.cell.2024.10.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39547211</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Divyanshu Tiwari</dc:creator>
<dc:creator>Nabarun Roy</dc:creator>
<dc:creator>Arun K Shukla</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Bound by the love for cholesterol: A transporter meets a GPCR</dc:title>
<dc:identifier>pmid:39547211</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.033</dc:identifier>
</item>
<item>
<title>Discovery and significance of protein-protein interactions in health and disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39547210/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116231315&amp;v=2.18.0.post9+e462414
      <description>The identification of individual protein-protein interactions (PPIs) began more than 40 years ago, using protein affinity chromatography and antibody co-immunoprecipitation. As new technologies emerged, analysis of PPIs increased to a genome-wide scale with the introduction of intracellular tagging methods, affinity purification (AP) followed by mass spectrometry (MS), and co-fractionation MS (CF-MS). Now, combining the resulting catalogs of interactions with complementary methods, including...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 14;187(23):6501-6517. doi: 10.1016/j.cell.2024.10.038.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The identification of individual protein-protein interactions (PPIs) began more than 40 years ago, using protein affinity chromatography and antibody co-immunoprecipitation. As new technologies emerged, analysis of PPIs increased to a genome-wide scale with the introduction of intracellular tagging methods, affinity purification (AP) followed by mass spectrometry (MS), and co-fractionation MS (CF-MS). Now, combining the resulting catalogs of interactions with complementary methods, including crosslinking MS (XL-MS) and cryogenic electron microscopy (cryo-EM), helps distinguish direct interactions from indirect ones within the same or between different protein complexes. These powerful approaches and the promise of artificial intelligence applications like AlphaFold herald a future where PPIs and protein complexes, including energy-driven protein machines, will be understood in exquisite detail, unlocking new insights in the contexts of both basic biology and disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39547210/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116231315&v=2.18.0.post9+e462414">39547210</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.038>10.1016/j.cell.2024.10.038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39547210</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jack F Greenblatt</dc:creator>
<dc:creator>Bruce M Alberts</dc:creator>
<dc:creator>Nevan J Krogan</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Discovery and significance of protein-protein interactions in health and disease</dc:title>
<dc:identifier>pmid:39547210</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.038</dc:identifier>
</item>
<item>
<title>The ribosome comes to life</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39547209/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116231315&amp;v=2.18.0.post9+e462414
      <description>The ribosome, together with its tRNA substrates, links genotype to phenotype by translating the genetic information carried by mRNA into protein. During the past half-century, the structure and mechanisms of action of the ribosome have emerged from mystery and confusion. It is now evident that the ribosome is an ancient RNA-based molecular machine of staggering structural complexity and that it is fundamentally similar in all living organisms. The three central functions of protein...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 14;187(23):6486-6500. doi: 10.1016/j.cell.2024.10.035.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The ribosome, together with its tRNA substrates, links genotype to phenotype by translating the genetic information carried by mRNA into protein. During the past half-century, the structure and mechanisms of action of the ribosome have emerged from mystery and confusion. It is now evident that the ribosome is an ancient RNA-based molecular machine of staggering structural complexity and that it is fundamentally similar in all living organisms. The three central functions of protein synthesis-decoding, catalysis of peptide bond formation, and translocation of mRNA and tRNA-are based on elegant mechanisms that evolved from the properties of RNA, the founding macromolecule of life. Moreover, all three of these functions (and even life itself) seem to proceed in defiance of entropy. Protein synthesis thus appears to exploit both the energy of GTP hydrolysis and peptide bond formation to constrain the directionality and accuracy of events taking place on the ribosome.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39547209/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116231315&v=2.18.0.post9+e462414">39547209</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.035>10.1016/j.cell.2024.10.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39547209</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Harry F Noller</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The ribosome comes to life</dc:title>
<dc:identifier>pmid:39547209</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.035</dc:identifier>
</item>
<item>
<title>Small and long non-coding RNAs: Past, present, and future</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39547208/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116231315&amp;v=2.18.0.post9+e462414
      <description>Since the introduction of the central dogma of molecular biology in 1958, various RNA species have been discovered. Messenger RNAs transmit genetic instructions from DNA to make proteins, a process facilitated by housekeeping non-coding RNAs (ncRNAs) such as small nuclear RNAs (snRNAs), ribosomal RNAs (rRNAs), and transfer RNAs (tRNAs). Over the past four decades, a wide array of regulatory ncRNAs have emerged as crucial players in gene regulation. In celebration of Cell's 50th anniversary, this...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 14;187(23):6451-6485. doi: 10.1016/j.cell.2024.10.024.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Since the introduction of the central dogma of molecular biology in 1958, various RNA species have been discovered. Messenger RNAs transmit genetic instructions from DNA to make proteins, a process facilitated by housekeeping non-coding RNAs (ncRNAs) such as small nuclear RNAs (snRNAs), ribosomal RNAs (rRNAs), and transfer RNAs (tRNAs). Over the past four decades, a wide array of regulatory ncRNAs have emerged as crucial players in gene regulation. In celebration of Cell's 50th anniversary, this Review explores our current understanding of the most extensively studied regulatory ncRNAs-small RNAs and long non-coding RNAs (lncRNAs)-which have profoundly shaped the field of RNA biology and beyond. While small RNA pathways have been well documented with clearly defined mechanisms, lncRNAs exhibit a greater diversity of mechanisms, many of which remain unknown. This Review covers pivotal events in their discovery, biogenesis pathways, evolutionary traits, action mechanisms, functions, and crosstalks among ncRNAs. We also highlight their roles in pathophysiological contexts and propose future research directions to decipher the unknowns of lncRNAs by leveraging lessons from small RNAs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39547208/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116231315&v=2.18.0.post9+e462414">39547208</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.024>10.1016/j.cell.2024.10.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39547208</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Ling-Ling Chen</dc:creator>
<dc:creator>V Narry Kim</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Small and long non-coding RNAs: Past, present, and future</dc:title>
<dc:identifier>pmid:39547208</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.024</dc:identifier>
</item>
<item>
<title>The chromosome folding problem and how cells solve it</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39547207/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116231315&amp;v=2.18.0.post9+e462414
      <description>Every cell must solve the problem of how to fold its genome. We describe how the folded state of chromosomes is the result of the combined activity of multiple conserved mechanisms. Homotypic affinity-driven interactions lead to spatial partitioning of active and inactive loci. Molecular motors fold chromosomes through loop extrusion. Topological features such as supercoiling and entanglements contribute to chromosome folding and its dynamics, and tethering loci to sub-nuclear structures adds...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 14;187(23):6424-6450. doi: 10.1016/j.cell.2024.10.026.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Every cell must solve the problem of how to fold its genome. We describe how the folded state of chromosomes is the result of the combined activity of multiple conserved mechanisms. Homotypic affinity-driven interactions lead to spatial partitioning of active and inactive loci. Molecular motors fold chromosomes through loop extrusion. Topological features such as supercoiling and entanglements contribute to chromosome folding and its dynamics, and tethering loci to sub-nuclear structures adds additional constraints. Dramatically diverse chromosome conformations observed throughout the cell cycle and across the tree of life can be explained through differential regulation and implementation of these basic mechanisms. We propose that the first functions of chromosome folding are to mediate genome replication, compaction, and segregation and that mechanisms of folding have subsequently been co-opted for other roles, including long-range gene regulation, in different conditions, cell types, and species.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39547207/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116231315&v=2.18.0.post9+e462414">39547207</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.026>10.1016/j.cell.2024.10.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39547207</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Job Dekker</dc:creator>
<dc:creator>Leonid A Mirny</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The chromosome folding problem and how cells solve it</dc:title>
<dc:identifier>pmid:39547207</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.026</dc:identifier>
</item>
<item>
<title>The cellular dogma</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39547206/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116231315&amp;v=2.18.0.post9+e462414
      <description>In this essay, I will put forth what I see as a major conceptual challenge for biology in the next decade, one that is inspired by Crick's Central Dogma: understanding information flow in the cell in the most general sense.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 14;187(23):6421-6423. doi: 10.1016/j.cell.2024.10.029.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In this essay, I will put forth what I see as a major conceptual challenge for biology in the next decade, one that is inspired by Crick's Central Dogma: understanding information flow in the cell in the most general sense.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39547206/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116231315&v=2.18.0.post9+e462414">39547206</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.029>10.1016/j.cell.2024.10.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39547206</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Stephen R Quake</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The cellular dogma</dc:title>
<dc:identifier>pmid:39547206</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.029</dc:identifier>
</item>
<item>
<title>From bacterial operons to gene therapy: 50 years of the journal Cell</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39547205/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116231315&amp;v=2.18.0.post9+e462414
      <description>Recombinant DNA technology has profoundly advanced virtually every aspect of biological and medical sciences, from basic research to biotechnology. Here, I discuss conceptual connections linking fundamental discoveries that were enabled by the technology, advances in the understanding of gene regulation in both prokaryotes and eukaryotes, and the recent FDA-approved CRISPR-based gene therapy for sickle cell anemia and β-thalassemia based on transcriptional derepression.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 14;187(23):6417-6420. doi: 10.1016/j.cell.2024.10.037.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Recombinant DNA technology has profoundly advanced virtually every aspect of biological and medical sciences, from basic research to biotechnology. Here, I discuss conceptual connections linking fundamental discoveries that were enabled by the technology, advances in the understanding of gene regulation in both prokaryotes and eukaryotes, and the recent FDA-approved CRISPR-based gene therapy for sickle cell anemia and β-thalassemia based on transcriptional derepression.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39547205/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116231315&v=2.18.0.post9+e462414">39547205</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.037>10.1016/j.cell.2024.10.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39547205</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Tom Maniatis</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>From bacterial operons to gene therapy: 50 years of the journal Cell</dc:title>
<dc:identifier>pmid:39547205</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.037</dc:identifier>
</item>
<item>
<title>Molecular biology: The fundamental science fueling innovation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39547204/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116231315&amp;v=2.18.0.post9+e462414
      <description>Molecular biology aims to understand the details of life by focusing closely on biopolymers-DNAs, RNAs, and proteins-and how they interact with one another. Advances in this field have enabled dazzling achievements in virtually all areas of biological, biomedical, and clinical sciences. As we draw near to the conclusion of Cell's 50^(th) anniversary, we celebrate the wonders of molecular biology and look ahead to the exciting path forward for a branch of science that is driven by curiosity and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 14;187(23):6415-6416. doi: 10.1016/j.cell.2024.10.043.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Molecular biology aims to understand the details of life by focusing closely on biopolymers-DNAs, RNAs, and proteins-and how they interact with one another. Advances in this field have enabled dazzling achievements in virtually all areas of biological, biomedical, and clinical sciences. As we draw near to the conclusion of Cell's 50<sup>th</sup> anniversary, we celebrate the wonders of molecular biology and look ahead to the exciting path forward for a branch of science that is driven by curiosity and has always been an integral part of the journal.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39547204/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116231315&v=2.18.0.post9+e462414">39547204</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.043>10.1016/j.cell.2024.10.043</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39547204</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Cell editorial team</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Molecular biology: The fundamental science fueling innovation</dc:title>
<dc:identifier>pmid:39547204</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.043</dc:identifier>
</item>
<item>
<title>Interpreting Population Mean Treatment Effects in the Kansas City Cardiomyopathy Questionnaire: A Patient-Level Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39546393/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116231315&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Inferences about clinical impacts based on population-level mean treatment effects may be misleading, since even small between-group differences may reflect clinically important treatment benefits for individual patients. Results of this study suggest that clinical trials should explicitly describe the distributions of KCCQ change at the patient level within treatment groups to support the clinical interpretation of their results.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 15. doi: 10.1001/jamacardio.2024.4470. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a commonly used outcome in heart failure trials. While comparing means between treatment groups improves statistical power, mean treatment effects do not necessarily reflect the clinical benefit experienced by individual patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the association between mean KCCQ treatment effects and the proportions of patients experiencing clinically important improvements across a range of clinical trials and heart failure etiologies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: A patient-level analysis of 11 randomized clinical trials, including 9977 patients, was performed to examine the association between mean treatment effects and the KCCQ Overall Summary Score (OSS) and the absolute differences in the proportions of patients experiencing clinically important (≥5 points) and moderate to large (≥10 points) improvements. There was no target date range, and included studies were those for which patient-level data were available. Validation was performed in 7 additional trials. The data were analyzed between July 1 and September 15, 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Proportion of patients experiencing an improvement of 5 or more and 10 or more points in their KCCQ score (with each domain transformed to a range of 0 to 100 points, where higher scores represent better health status).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Group mean KCCQ-OSS differences were strongly correlated with absolute differences in clinically important changes (Spearman correlations 0.76-0.92). For example, a mean KCCQ-OSS treatment effect of 2.5 points (half of a minimally important difference for an individual patient) was associated with an absolute difference of 6.0% (95% prediction interval [PI], 4.0%-8.1%) in the proportion of patients improving 5 or more points and 5.0% (95% PI, 3.1%-7.0%) in the proportion improving 10 or more points, corresponding to a number needed to treat of 17 (95% PI, 12-25) and 20 (95% PI, 14-33), respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Inferences about clinical impacts based on population-level mean treatment effects may be misleading, since even small between-group differences may reflect clinically important treatment benefits for individual patients. Results of this study suggest that clinical trials should explicitly describe the distributions of KCCQ change at the patient level within treatment groups to support the clinical interpretation of their results.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39546393/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116231315&v=2.18.0.post9+e462414">39546393</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4470>10.1001/jamacardio.2024.4470</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39546393</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Mohammad Abdel Jawad</dc:creator>
<dc:creator>Philip G Jones</dc:creator>
<dc:creator>Suzanne V Arnold</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>Charles F Sherrod</dc:creator>
<dc:creator>Mirza S Khan</dc:creator>
<dc:creator>Nobuhiro Ikemura</dc:creator>
<dc:creator>Paul S Chan</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Interpreting Population Mean Treatment Effects in the Kansas City Cardiomyopathy Questionnaire: A Patient-Level Meta-Analysis</dc:title>
<dc:identifier>pmid:39546393</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4470</dc:identifier>
</item>
<item>
<title>Interpreting Health Status Measures in Patients With Heart Failure-What Counts</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39546392/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116231315&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 15. doi: 10.1001/jamacardio.2024.4610. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39546392/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116231315&v=2.18.0.post9+e462414">39546392</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4610>10.1001/jamacardio.2024.4610</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39546392</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>James E Udelson</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Interpreting Health Status Measures in Patients With Heart Failure-What Counts</dc:title>
<dc:identifier>pmid:39546392</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4610</dc:identifier>
</item>
<item>
<title>Rural-Urban Differences in Cardiovascular Mortality in the United States, 2010-2022</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39545907/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116231315&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 23:S0735-1097(24)09779-1. doi: 10.1016/j.jacc.2024.09.1215. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39545907/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116231315&v=2.18.0.post9+e462414">39545907</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1215>10.1016/j.jacc.2024.09.1215</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39545907</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Lucas X Marinacci</dc:creator>
<dc:creator>ZhaoNian Zheng</dc:creator>
<dc:creator>Stephen Mein</dc:creator>
<dc:creator>Rishi K Wadhera</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Rural-Urban Differences in Cardiovascular Mortality in the United States, 2010-2022</dc:title>
<dc:identifier>pmid:39545907</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1215</dc:identifier>
</item>
<item>
<title>Sedentary Behavior and Risk of Cardiovascular Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39545906/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116231315&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 8:S0735-1097(24)10415-9. doi: 10.1016/j.jacc.2024.11.002. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39545906/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116231315&v=2.18.0.post9+e462414">39545906</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.002>10.1016/j.jacc.2024.11.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39545906</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Charles B Eaton</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Sedentary Behavior and Risk of Cardiovascular Disease</dc:title>
<dc:identifier>pmid:39545906</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.002</dc:identifier>
</item>
<item>
<title>P2Y&lt;sub>;12&lt;/sub>; Inhibitor Pretreatment in Non-ST-Segment Elevation Acute Coronary Syndrome: The NCDR Chest Pain-MI Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39545905/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241116231315&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In a national U.S. registry, we observed significant variability in the use of P2Y(12) inhibitor pretreatment among NSTE-ACS patients. Given the lack of clear advantages and the potential for prolonged hospital stays, our findings highlight the importance of efforts to improve standardization.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 7:S0735-1097(24)09843-7. doi: 10.1016/j.jacc.2024.09.1227. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Although high rates of P2Y<sub>12</sub> inhibitor pretreatment (defined as the administration before coronary angiography) for non-ST-segment elevation acute coronary syndrome (NSTE-ACS) have been reported, contemporary U.S. practice patterns are not well studied.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to investigate the temporal U.S. trends, variability, and clinical outcomes of P2Y<sub>12</sub> inhibitor pretreatment in NSTE-ACS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Consecutive patients who underwent early invasive strategy for NSTE-ACS (coronary angiography ≤24 hours of arrival) in the National Cardiovascular Data Registry Chest Pain-Myocardial Infarction (MI) Registry were analyzed. A time-trend analysis was conducted on a complete cohort between January 1, 2013, and March 31, 2023. Subsequently, a more recent cohort (January 1, 2019, to March 31, 2023) with a complete set of variables was used to construct hierarchical regression models to quantify the variability in the use of pretreatment among operators and institutions. For this contemporary cohort, instrumental variable analysis, with operator preference as the instrument, was performed to compare the in-hospital outcomes between patients who received pretreatment and those who did not.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Use of P2Y<sub>12</sub> inhibitor pretreatment decreased from 24.8% in 2013Q1 to 12.4% in 2023Q1. Among the contemporary cohort of 110,148 patients (2019-2023; mean age 63.9 ± 12.5 years; 33.0% female), 17,509 (15.9%) received pretreatment. Significant variability in P2Y<sub>12</sub> inhibitor pretreatment was observed (range: 0%-100%): hierarchical regression model demonstrated that 2 similar patients would have a >;3-fold difference in the odds of pretreatment from 1 random operator or institution as compared with another (median OR: 3.74 [95% CI: 3.57-3.91] and 3.63 [95% CI: 3.51-3.74], respectively). Instrumental variable analysis demonstrated no significant differences in in-hospital all-cause death (1.5% vs 1.7%; P = 0.07), recurrent MI (0.6% vs 0.6%; P = 0.98), or major bleeding (2.7% vs 2.8%; P = 0.98) with pretreatment. However, in patients who underwent coronary artery bypass surgery, pretreatment was associated with a longer length of stay (11.2 ± 5.1 days vs 9.8 ± 5.0 days; P &lt; 0.01).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In a national U.S. registry, we observed significant variability in the use of P2Y<sub>12</sub> inhibitor pretreatment among NSTE-ACS patients. Given the lack of clear advantages and the potential for prolonged hospital stays, our findings highlight the importance of efforts to improve standardization.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39545905/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241116231315&v=2.18.0.post9+e462414">39545905</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1227>10.1016/j.jacc.2024.09.1227</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39545905</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Hiroki A Ueyama</dc:creator>
<dc:creator>Kevin F Kennedy</dc:creator>
<dc:creator>Jennifer A Rymer</dc:creator>
<dc:creator>Alexander T Sandhu</dc:creator>
<dc:creator>Toshiki Kuno</dc:creator>
<dc:creator>Frederick A Masoudi</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>Shun Kohsaka</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>P2Y&lt;sub>;12&lt;/sub>; Inhibitor Pretreatment in Non-ST-Segment Elevation Acute Coronary Syndrome: The NCDR Chest Pain-MI Registry</dc:title>
<dc:identifier>pmid:39545905</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1227</dc:identifier>
</item>





























</channel>
</rss>